Press Releases April 21, 2026 08:45 AM

Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call

Fortrea schedules Q1 2026 earnings release and conference call for May 5, 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
FTRE

Fortrea, a global contract research organization, announced it will release its Q1 2026 financial results before the market opens on May 5, 2026, followed by a conference call at 8:00 a.m. ET to discuss the results. The company specializes in clinical development solutions spanning various therapeutic areas and operates globally.

Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call
FTRE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Fortrea will announce its first quarter 2026 financial results on May 5, 2026 before market open.
  • A conference call to discuss the results will be held at 8:00 a.m. ET on the same day, accessible via pre-registration and live webcast.
  • Fortrea operates in the clinical development and contract research sector, providing services across over 20 therapeutic areas globally.

DURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.

To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call.

The live webcast can be accessed at investors.fortrea.com. A replay will be available in the Events and Presentations section of the site following the conclusion of the call.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team, operating across approximately 100 countries, is scaled to deliver focused, agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts

Tracy Krumme (Investors) – 984-385-6707, [email protected]
Sue Zaranek (Media) – 919-943-5422, [email protected]
Kate Dillon (Media) – 646-818-9115, [email protected]


Risks

  • Financial results may not meet investor expectations leading to stock volatility in biotech and healthcare sectors.
  • Global operations expose Fortrea to geopolitical and regulatory risks affecting clinical trial continuity.
  • Dependence on client biopharmaceutical companies' drug development pipelines could impact revenue if clinical programs are delayed or canceled.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026